title: Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease.
abstract: Impaired cholinergic function in the central nervous system is an early feature of Alzheimer disease (AD). Currently, cholinergic deficit is usually corrected by increasing the amount of acetylcholine in the synapse by inhibiting acetylcholinesterase (AChE). One of the most consistent cholinergic deficits in AD is the reduced expression of nicotinic acetylcholine receptors (nAChR) in the brain. Since these receptors are essential for learning and memory, restoring nicotinic cholinergic function is a promising approach to treating AD. Allosteric modulation of nAChR is a novel approach, which circumvents development of tolerance through long-term use of conventional nicotinic agonists. Allosteric modulators interact with receptor-binding sites distinct from those capable of recognizing the natural agonist. Positive allosteric modulation of nAChR activity has no effect on conductance of single channels; instead, by facilitating channel opening, it potentiates responses evoked by the interaction of the natural agonist with presynaptic and postsynaptic nAChR. Allosteric modulation of nAChR activity could therefore potentially produce a significant benefit in AD. One such allosteric modulator is galantamine. In addition to increasing nAChR activity, galantamine also inhibits AChE. This novel, dual mechanism of action distinguishes galantamine from many other AChE inhibitors. Galantamine has been shown to improve cognitive and daily function for at least 6 months in placebo-controlled trials, and to maintain these functions at baseline levels for at least 12 months in a 6-month open-label extension study. Galantamine has positive effects on nAChR expression, which are likely to contribute to its sustained efficacy in the treatment of AD patients.
authors.affiliation: Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore 21201, USA. ealbuque@umaryland.edu
authors.forename: E X
authors.initials: EX
authors.lastname: Albuquerque
authors.forename: M D
authors.initials: MD
authors.lastname: Santos
authors.forename: M
authors.initials: M
authors.lastname: Alkondon
authors.forename: E F
authors.initials: EF
authors.lastname: Pereira
authors.forename: A
authors.initials: A
authors.lastname: Maelicke
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000203:Activities of Daily Living / Q000145:classification; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D005702:Galantamine / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D011978:Receptors, Nicotinic / Q000187:drug effects* / Q000502:physiology
chemical_list: D018697:Nootropic Agents; D011978:Receptors, Nicotinic; D005702:Galantamine; D000109:Acetylcholine